VECT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (8 Jul 2023 @ 03:59):

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions...

Stats
今日成交量	127 653
平均成交量	1.10M
市值	1.06B
EPS	$0 ( 2023-07-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.03
ATR14	$0.430 (2.55%)

音量相关性

長: 0.33 (neutral)

短: -0.50 (neutral)

Signal:(67.1) Neutral

VectivBio Holding AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

VectivBio Holding AG 相关性 - 货币/商品

0.82
( strong )

0.17
( neutral )

0.49
( neutral )

0.53
( weak )

-0.79
( moderate negative )

VectivBio Holding AG 财务报表

Annual	2022
营收:	$27.34M
毛利润:	$27.34M (100.00 %)
EPS:	$-2.12

FY	2022
营收:	$27.34M
毛利润:	$27.34M (100.00 %)
EPS:	$-2.12

Financial Reports:

No articles found.

VectivBio Holding AG

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.